Fusion protein comprising the extracellular domain of a filovirus glycoprotein fused to an immunoglobulin heavy chain constant region
This invention provides fusion proteins comprising a Filovirus glycoprotein segment and an immunoglobulin polypeptide segment. The fusion proteins are useful in immunogenic compositions to protect against infections by Filoviruses, such as Ebola virus, in both humans and non-human animals. The fusion proteins are also useful in diagnostic assays to detect Filovirus infections.
1. A fusion protein comprising a Filovirus glycoprotein segment comprising an extracellular domain and an immunoglobulin polypeptide segment comprising an immunoglobulin heavy chain constant domain polypeptide, wherein the C-terminus of the Filovirus glycoprotein segment is attached to the N-terminus of the immunoglobulin polypeptide segment.
2. The fusion protein of claim 1 , wherein the Filovirus glycoprotein segment is from an Ebola virus.
3. The fusion protein of claim 2 , wherein the Ebola virus is Zaire Ebola virus, Mayinga strain.
4. The fusion protein of claim 1 , wherein the immunoglobulin is IgG1.
5. The fusion protein of claim 1 , further comprising a linker between the Filovirus glycoprotein segment and the immunoglobulin polypeptide segment.
6. The fusion protein of claim 1 , which has the sequence as shown in SEQ ID NO: 2.
7. An immunogenic composition comprising the fusion protein of claim 1 .
8. The immunogenic composition of claim 7 , further comprising an adjuvant.
9. A method of detecting an immune response against Filovirus in a patient, the method comprising contacting a biological sample from the patient with the fusion protein of claim 1 and detecting an immune response.
10. The method of claim 9 , wherein the step of detecting an immune response includes the step of detecting binding of antibodies in the biological sample to the fusion protein.
11. The method of claim 10 , wherein the step of detecting binding of antibodies is carried by ELISA, a chemiluminescence assay, or a fluorescence assay.
12. The method of claim 9 , wherein the step of detecting an immune response includes the step of detecting a cellular immune response.
13. The method of claim 12 , wherein the step of detecting a cellular immune response is carried by detecting IFN-γ or TNF-α.